Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study

Conclusions: In patients with IPF who received nintedanib in the FIBRONET study, FVC% predicted was stable over 12 months, and the proportion of patients with cough decreased. The safety profile was consistent with the known safety profile for nintedanib in IPF.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research